|
시장보고서
상품코드
1983159
식도암 치료제 시장 : 치료 유형별, 적응증별, 유통 채널별, 지역별Esophageal Cancer Drugs Market, By Therapy Type, By Disease Indication, By Distribution Channel, By Geography |
||||||
식도암 치료제 시장은 2026년에 47억 8,000만 달러로 추정되고 있으며, 2033년까지 67억 8,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.7%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 47억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 6.70% | 2033년 시장 규모 예측 : | 67억 8,000만 달러 |
식도암은 식도 안쪽을 덮고 있는 세포에서 발생합니다. 주요 증상으로는 연하곤란(삼킴장애), 의도파관 않은 체중감소, 흉통, 소화불량 및 속쓰림 악화, 기침, 쉰 목소리 등이 있습니다. 도세탁셀, 트리플루리진, 티피라실 염산염 등 미국 식품의약국(FDA)의 승인을 받은 약물은 식도암 치료에 널리 사용되는 화학요법제입니다. 또한 펨브롤리주맙이라는 면역치료제도 식도암 치료에 사용되고 있습니다. 2017년 FDA는 재발한 국소 진행성 또는 전이성 위암 또는 위식도 접합부 선암 환자를 대상으로 펨브롤리주맙(키트루다)을 조기 승인했습니다.
시장 역학
세계에서 식도암의 유병률이 증가함에 따라 식도암 치료제 시장의 성장을 촉진할 것으로 예측됩니다. 세계암연구기금(WCRF) 인터내셔널의 2018년 보고서에 따르면 식도암은 남성에서 7번째로 흔한 암이며, 여성에서는 13번째로 흔한 암입니다. 2018년에는 전 세계에서 50만 건 이상의 새로운 사례가 보고되었습니다. 또한 노인은 식도암 발병 위험이 높고, 남성은 식도암에 걸리기 쉬운 경향이 있습니다. 예를 들어 2018년 미국임상종양학회(ASCO)가 발표한 자료에 따르면 45세에서 70세 사이의 사람들이 식도암에 걸릴 위험이 가장 높은 것으로 추정됩니다.
그러나 식도암을 완전히 완치시키는 약물요법은 존재하지 않으며, 치료 시작 후 5년이 지나면 식도암 환자의 생존율은 현저히 떨어집니다. 식도암 치료제는 치료 시작 후 5년이 지나면 효과를 기대할 수 없으며, 이는 식도암 치료제 시장의 성장을 저해하는 요인으로 작용할 것으로 예측됩니다. 예를 들어 2019년 1월 ASCO에서 발표된 연구에 따르면 식도암 환자의 5년 생존율은 19%입니다.
본 조사의 주요 특징.
- 이 보고서는 2025년을 기준 연도로 하여 2026-2033년의 예측 기간 중 식도암 치료제 시장, 시장 규모 및 CAGR(%)에 대한 상세한 분석을 제공합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 지역, 유통 전략, 주요 개발 및 전략과 같은 매개 변수를 기반으로 세계 식도암 치료제 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부 주도 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 시장 진출기업, 금융 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 식도암 치료제 시장 : 치료 유형별, 2026-2033년
제5장 세계의 식도암 치료제 시장 : 적응증별, 2026-2033년
제6장 세계의 식도암 치료제 시장 : 유통 채널별, 2026-2033년
제7장 세계의 식도암 치료제 시장 : 지역별, 2026-2033년
제8장 경쟁 구도
제9장 애널리스트의 추천
제10장 섹션
KSA 26.04.20Esophageal Cancer Drugs Market is estimated to be valued at USD 4.78 Bn in 2026 and is expected to reach USD 6.78 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.70% | 2033 Value Projection: | USD 6.78 Bn |
Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.
Market Dynamics
Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.
However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.
Key features of the study
- This report provides in-depth analysis of the esophageal cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global esophageal cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Therapy Type
- Chemotherapy
- Docetaxel
- Irinotecan
- Trifluridine
- Tipiracil
- Carboplatin and Paclitaxel
- Cisplatin
- 5-fluorouracil
- Cisplatin with Capecitabine
- Targeted Drug Therapy
- Trastuzumab
- Ramucirumab
- Immunotherapy (Pembrolizumab)
- By Disease Indication
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Squamous Cell Carcinoma
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen Inc.
- Eli Lilly and Company
- Hoffmann-La Roche
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- GlaxoSmithKline Plc.
- Novartis AG
- Johnson & Johnson
- Gilead Sciences
- Genentech, Inc.
- Sanofi-Aventis
- Merck & Co.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Esophageal Cancer Drugs Market, By Therapy Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Chemotherapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Docetaxel
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Irinotecan
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Trifluridine and Tipiraci
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Carboplatin and Paclitaxel
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cisplatin and 5-fluorouracil
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cisplatin with Capecitabine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Targeted Drug Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Trastuzumab
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ramucirumab
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Immunotherapy (Pembrolizumab)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adenocarcinomas
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Gastrointestinal Stromal Tumors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Carcinoid Tumors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Squamous Cell Carcinoma
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Esophageal Cancer Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Esophageal Cancer Drugs Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Amgen Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Eli Lilly and Company
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- F. Hoffmann-La Roche
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Bristol-Myers Squibb Company
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Boehringer Ingelheim GmbH
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Bristol-Myers Squibb
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- GlaxoSmithKline Plc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Novartis AG
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Johnson & Johnson
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Gilead Sciences
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Genentech, Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Sanofi-Aventis
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Merck & Co
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Amgen Inc.
9. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. Section
- References
- Research Methodology
- About Us and Sales Contact
